Citigroup
PCRX icon

Citigroup’s Pacira BioSciences PCRX Stock Holding History

Citigroup’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-600
Closed -$20K – 7640
2020
Q1 		$20K Sell
600
-1,200
-67% -$49.8K ﹤0.01% 6695
2019
Q4 		$82K Sell
1,800
-1,500
-45% -$63.7K ﹤0.01% 5935
2019
Q3 		$126K Sell
3,300
-6,600
-67% -$263K ﹤0.01% 5510
2019
Q2 		$431K Buy
9,900
+8,800
+800% +$374K ﹤0.01% 4564
2019
Q1 		$42K Sell
1,100
-400
-27% -$15.6K ﹤0.01% 6470
2018
Q4 		$65K Sell
1,500
-33,100
-96% -$1.55M ﹤0.01% 6017
2018
Q3 		$1.7M Buy
34,600
+32,900
+1,935% +$1.42M ﹤0.01% 2913
2018
Q2 		$54K Sell
1,700
-6,100
-78% -$211K ﹤0.01% 6227
2018
Q1 		$243K Buy
7,800
+4,600
+144% +$164K ﹤0.01% 4761
2017
Q4 		$146K Buy
3,200
+2,600
+433% +$103K ﹤0.01% 5312
2017
Q3 		$23K Sell
600
-5,900
-91% -$237K ﹤0.01% 6398
2017
Q2 		$310K Sell
6,500
-4,100
-39% -$190K ﹤0.01% 4419
2017
Q1 		$483K Buy
10,600
+4,300
+68% +$186K ﹤0.01% 3894
2016
Q4 		$203K Sell
6,300
-2,100
-25% -$70.1K ﹤0.01% 5262
2016
Q3 		$287K Buy
+8,400
New +$329K ﹤0.01% 4384

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's PCRX Position: Q1 2026 in Review

Citigroup reduced its Pacira BioSciences (PCRX) stake by 17% in Q1 2026, selling an estimated $129K and leaving 29,117 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

Citigroup first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.62M in Q2 2017. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Citigroup held 29,117 shares of Pacira BioSciences worth $658K as of Q1 2026.
  • Citigroup sold 5,825 Pacira BioSciences shares in Q1 2026, an estimated $129K.
  • Pacira BioSciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3383 holding.
  • Citigroup first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Pacira BioSciences position peaked at $4.62M in Q2 2017.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.